Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)

184
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
10/14/2014 10/15/2014 10/16/2014 10/17/2014 10/20/2014 Date
264.5(c) 258.9(c) 260.5(c) 267.7(c) 268.6(c) Last
1 372 563 2 249 887 3 935 279 4 403 050 1 449 233 Volume
+0.15% -2.12% +0.62% +2.76% +0.34% Change
More quotes
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
11/11Presentation
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Financials ( CHF)
Sales 2014 47 251 M
EBIT 2014 17 561 M
Net income 2014 11 961 M
Debt 2014 6 217 M
Yield 2014 3,06%
Sales 2015 49 572 M
EBIT 2015 18 826 M
Net income 2015 13 028 M
Debt 2015 669 M
Yield 2015 3,30%
PER 2014 19,08
PER 2015 17,38
EV / Sales 2014 5,01x
EV / Sales 2015 4,66x
Capitalization 230 388 M
More Financials
Latest news on ROCHE HOLDING LTD.
5d ago ROCHE : Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® an..
5d ago New breast cancer drugs boost sales at Roche
6d ago ROCHE : FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulm..
10/13DJRoche Holding 3Q 2014 -- Forecast
10/08 ROCHE : FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Re..
10/08 NOVARTIS : Shareholder group critical as Roche and Novartis chiefs top Swiss pay..
09/29 ROCHE : Genentech :’s Investigational Combination of Cobimetinib Plus Zelb..
09/28 ROCHE : Genentech :’s Perjeta Regimen Extended the Lives of People With an..
09/24 Adaptimmune raises $104 million to develop immune-system cancer drugs
09/17 For Roche CEO, celebrating failure is key to success
09/16 Roche's $8 billion InterMune buy not a signal for more big deals
09/08 Cost a focus as GSK takes lead in new wave of biotech lung drugs
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF